Literature DB >> 26996159

Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy.

Molin Wongwattanakul1,2,3, Chariya Hahnvajanawong2,4, Patcharaporn Tippayawat1, Sirinart Chio-Srichan5, Chanvit Leelayuwat1,2, Temduang Limpaiboon1,2, Patcharee Jearanaikoon1,2, Philip Heraud6,7.   

Abstract

Cholangiocarcinoma (CCA), a cancer of bile duct epithelium, is a major health problem in Thailand especially in the northeast. Overall treatment outcomes have not shown much improvement because the disease is usually detected at an advanced stage and often shows chemotherapeutic resistance. High-throughput Fourier Transform Infrared (FTIR) microspectroscopy can be used for cell classification and has the potential to diagnose cancer and possibly predict chemo-response. This study was aimed to differentiate gemcitabine-sensitive and gemcitabine-resistant induction in two CCA cell lines (KKU-M139 and KKU-M214) and xenograft tissues using synchrotron-FTIR microspectroscopy. Partial Least Squares Discriminant Analysis (PLS-DA) could discriminate between chemo-sensitive and chemo-resistant cells in the FTIR fingerprint spectral region (1800-1000 cm-1 ) with more than 90% sensitivity and specificity. The chemo-resistant and chemo-sensitive phenotypes were different in protein (amide I, amide II), lipids (carbonyl group and CH3 deformation) and phosphodiester from nucleic acids. Additionally, spectra from xenograft tissues showed similar results to the cell line study with marked differences between chemo-resistant and chemo-sensitive CCA tissues, and PLS-DA could discriminate the chemotherapeutic response with 98% sensitivity and specificity. This is the first study to demonstrate the use of FTIR microspectroscopy to assess chemo-response both in vitro and in vivo.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Cholangiocarcinoma; Synchrotron-FTIR; animal model; cell lines; chemo-resistance

Mesh:

Substances:

Year:  2016        PMID: 26996159     DOI: 10.1002/jbio.201500253

Source DB:  PubMed          Journal:  J Biophotonics        ISSN: 1864-063X            Impact factor:   3.207


  3 in total

1.  Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.

Authors:  Ricuphan Khamko; Wiphawan Wasenang; Jureerut Daduang; Chatri Settasatian; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

2.  Probing the Anti-Cancer Potency of Sulfated Galactans on Cholangiocarcinoma Cells Using Synchrotron FTIR Microspectroscopy, Molecular Docking, and In Vitro Studies.

Authors:  Boonyakorn Boonsri; Kiattawee Choowongkomon; Buabarn Kuaprasert; Thanvarin Thitiphatphuvanon; Kittiya Supradit; Apinya Sayinta; Jinchutha Duangdara; Tawut Rudtanatip; Kanokpan Wongprasert
Journal:  Mar Drugs       Date:  2021-04-30       Impact factor: 5.118

3.  Characterisation of breast cancer molecular signature and treatment assessment with vibrational spectroscopy and chemometric approach.

Authors:  Magdalena Kołodziej; Ewa Kaznowska; Sylwia Paszek; Józef Cebulski; Edyta Barnaś; Marian Cholewa; Jitraporn Vongsvivut; Izabela Zawlik
Journal:  PLoS One       Date:  2022-03-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.